Advancing Cell Therapies
to Transform
Solid Tumor Care

About

Bridging biotech
from bench to bedside.

PhryctaBio is a clinical-stage biotechnology company focused on developing transformative immune cell therapies for solid tumors. We have built a diversified pipeline to address significant unmet needs, tackling key barriers in solid tumor immunotherapy, including immune resistance, antigen heterogeneity, and post-ablation recurrence.